Hence, to differentiate the possible effects of Pg on the risk phase versus arthritis phase, we have analysed anti-Rgp IgG in a large prospective ACPA-positive at-risk cohort, where 37% developed arthritis during the study period. This evidence concerns the gene PRTN3 and arthritic joint disease.